Our current projects

Proprietary

Project & Mechanism
Disease areas
Preclinical
Phase I
Phase II
Phase III
Market

Remetinostat

Topical HDAC inhibitor

Cutaneous T-cell lymphoma - Phase II

Birinapant

SMAC mimetic

Solid tumors (Keytruda® combination) - Phase I

MIV-818

Nucleotide DNA polymerase inhibitor

Hepatocellular carcinoma - Pre-clinical

MIV-711

Cathepsin K inhibitor

Osteoarthritis - Phase II

Partnerships

Project & Mechanism
Disease areas
Preclinical
Phase I
Phase II
Phase III
Market

MIV-802

Nucleotide NS5B polymerase inhibitor

Hepatitis C - Phase I

Xerclear® (Zoviduo®)

Hydrocortisone and aciclovir combination

Labial herpes

Our current projects

Proprietary

Remetinostat

Topical HDAC inhibitor

  • Mechanism

    Topical HDAC inhibitor

  • Disease area

    Cutaneous T-cell lymphoma - Phase II

    Phase II

Birinapant

SMAC mimetic

  • Mechanism

    SMAC mimetic

  • Disease area

    Solid tumors (Keytruda® combination) - Phase I

    Phase I

MIV-818

Nucleotide DNA polymerase inhibitor

  • Mechanism

    Nucleotide DNA polymerase inhibitor

  • Disease area

    Hepatocellular carcinoma - Pre-clinical

    Preclinical

MIV-711

Cathepsin K inhibitor

  • Mechanism

    Cathepsin K inhibitor

  • Disease area

    Osteoarthritis - Phase II

    Phase II

Partnerships

MIV-802

Nucleotide NS5B polymerase inhibitor

  • Mechanism

    Nucleotide NS5B polymerase inhibitor

  • Disease area

    Hepatitis C - Phase I

    Preclinical

Xerclear® (Zoviduo®)

Hydrocortisone and aciclovir combination

  • Mechanism

    Hydrocortisone and aciclovir combination

  • Disease area

    Labial herpes

    Market